Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
12.22
-0.99 (-7.53%)
At close: Mar 18, 2026, 4:00 PM EDT
12.10
-0.12 (-0.98%)
After-hours: Mar 18, 2026, 4:10 PM EDT

Contineum Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
--50--
Gross Profit
--50--
Selling, General & Admin
16.5412.476.325.836.29
Research & Development
51.5238.4227.616.8922.36
Total Operating Expenses
68.0650.8933.9222.7228.65
Operating Income
-68.06-50.8916.08-22.72-28.65
Interest Income
8.258.914.610.760.08
Interest Expense
---0.21-0.39-0.33
Other Non-Operating Income (Expense)
-0.17-0.272.7-1.91-0.1
Total Non-Operating Income (Expense)
8.088.647.09-1.53-0.35
Pretax Income
-59.98-42.2623.17-24.25-29
Provision for Income Taxes
--0.45--
Net Income
-59.98-42.263.15-24.25-29
Net Income to Common
-59.98-42.263.15-24.25-29
Shares Outstanding (Basic)
2819222
Shares Outstanding (Diluted)
2819322
Shares Change (YoY)
43.14%469.95%51.38%6.50%-
EPS (Basic)
-2.17-2.181.36-10.81-13.77
EPS (Diluted)
-2.17-2.180.08-10.81-13.77
Free Cash Flow
-55.54-33.3618.94-20.24-26.43
Free Cash Flow Per Share
-2.01-1.725.58-9.02-
Gross Margin
--100.00%--
Operating Margin
--32.15%--
Profit Margin
--45.44%--
FCF Margin
--37.87%--
EBITDA
-67.74-50.6416.27-22.39-28.32
EBITDA Margin
--32.54%--
EBIT
-68.06-50.8916.08-22.72-28.65
EBIT Margin
--32.15%--
Effective Tax Rate
0.00%0.00%1.94%0.00%0.00%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q